Entries |
Document | Title | Date |
20080200559 | Substances Having Body Mass Redistribution Properties - There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass composition and/or ACE inhibiting activity or a physiologically acceptable derivative or prodrug thereof. | 08-21-2008 |
20080207770 | COMPOSITIONS ENRICHED IN PHENOLIC COMPOUNDS AND METHODS FOR PRODUCING THE SAME - Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably adsorbs the phenolic compounds but does not retain polar non-phenolic compounds, wherein the resin comprises aromatic rings substituted with one or more electron-withdrawing groups. This invention also includes compositions enriched in phenolic compounds. This invention encompasses methods of using the phenolic-enriched compositions for treating warm-blooded animals, including humans, infected with paramyxovaridae such as respiratory syncytial virus, orthomyoxovaridae such as influenza A, B, and C, parainfluenza, Herpes viruses such as HSV-1 and HSV-2, and Flaviviruses such as West Nile Virus, and for treating inflammation such as caused by arthritis, stress and digestive disease. The compositions are also useful as meat additives to inhibit food-borne pathogens. | 08-28-2008 |
20080262099 | Inhibition of Tumour Cell Migration - The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration. | 10-23-2008 |
20080269351 | ALKYLATED HYDROXYAROMATIC COMPOUND SUBSTANTIALLY FREE OF ENDOCRINE DISRUPTIVE CHEMICALS AND METHOD OF MAKING THE SAME - An alkylated hydroxyaromatic compound prepared by reacting at least one hydroxyaromatic compound with a branched olefinic oligomer having from about 20 to about 80 carbon atoms in the presence of a acid catalyst. The alkylated hydroxyaromatic compound has been determined to be substantially free of endocrine disruptive chemicals when the effects were quantified on pubertal development and thyroid function in the intact juvenile female rat. | 10-30-2008 |
20080275135 | Resorcinol Derivatives and Their Use for Lowering Blood Pressure - Disclosed are synthetic cannabinoids, namely resorcinol derivatives, which reduce blood pressure without having psychotropic effects. Pharmaceutical compositions for the treatment of high blood pressure related conditions, as well as methods of treating the same utilizing as active agent the compounds of the invention are also disclosed herein. Preferred active compounds are those which bear a long side chain on the C | 11-06-2008 |
20080312338 | Formulation - The invention relates to sterile pharmaceutical compositions for parenteral administration which comprise an oil-in-water emulsion in which a free radical scavenging sedative agent dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means for a surfactant, the composition being suitable either directly or after dilution with a liquid diluent for parenteral administration to a warm-blooded animal; in particular to such compositions comprising propofol, and which optionally further comprise a metal ion chelating agent (such as edetate), and the use of such compositions in improving survival in critically ill patients. | 12-18-2008 |
20090069445 | PROPOFOL-CONTAINING FAT EMULSIONS - This invention provides a propofol-containing fat emulsion preparation including: 0.1 to 2 w/v % of propofol, 10 to 20 w/v % of an oily component, and 2 to 5 w/v % of an emulsifier, the weight of the oily component being in the range of about 5 to about 200 times the weight of propofol, the weight of the emulsifier being in the range of about 0.9 to about 50 times that of propofol, and the average size of emulsion particles being 180 nm or less, and a method for preparing the same. Propofol-containing fat emulsion preparation of this invention alleviates the vascular pain that occurs during the administration thereof without incorporating a local anesthetic, such as lidocaine or the like, therein. | 03-12-2009 |
20090093549 | Aqueous Pharmaceutical Compositions Of 2,6-Diisopropylphenol (Propofol) And Their Uses - The present invention provides aqueous pharmaceutical compositions containing a lipophilic therapeutic agent. In particular, the invention provides aqueous pharmaceutical compositions containing the compound 2,6-diisopropylphenol (propofol). Preferred compositions of the invention contain propofol in the presence of at least one block copolymer (for example, P188 or another poloxamer) and a polyethylene glycol (PEG). Compositions of the invention are preferably sterile or are readily sterilized (e.g., by autoclaving) and are suitable for parenteral administration to any animal, including humans. The compositions are also chemically and physically stable over a wide range of environmental conditions and for extended periods of time. | 04-09-2009 |
20090131538 | Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate - Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of a pharmaceutically acceptable salt of formaldehyde sulfoxylate sufficient to prevent significant growth of microorganisms for at least 24 hours after adventitious contamination. | 05-21-2009 |
20090131539 | Mixture - A mixture of substances, in particular a biocide for combating human and animal parasites comprising a) an A component containing at least one type of alcohol of general formula R1-OH or R1-OH—R1′, wherein R1 and/or R1′ is an alkyl radical associated with a hydroxyl group which comprises from 1 to 12, preferably from 1 to 6, carbon atoms, b) a B component consisting of at least one type of carbonyl compound of formula R2-CO—R2′, wherein R2 and/or R2′ is an aryl-, alkyl- or cycloalkyl radical associated with a carbonyl group containing from 1 to 5, preferably from 1 to 2, carbon or hydrogen atoms, and c) at least one type of essential oil in the form of a C component consisting of an aromatic hydroxy compound of formula R3-0H, wherein R3 is a compound of at least one type of cyclic aryl radical which can be substituted up to two times and at least one organic compound R3′, wherein R3′ is an aryl-, alkyl- or cycloalkyl radical, wherein the components A and B are brought into reaction with hydrogen peroxide and the component C is subsequently mixed. | 05-21-2009 |
20090192230 | Propofol-containing fat emulsion preparation - The present invention provides a propofol-containing fat emulsion that can be administered with reduced vascular pain without incorporating a local anesthetic such as lidocaine; and a process for producing the same. The fat emulsion comprises 0.1 to 5 w/v % of propofol, 2 to 20 w/v % of an oily component, 0.4 to 10 w/v % of an emulsifier and 0.02 to 0.3 w/v % of at least one compound selected from the group consisting of cyclodextrins, cyclodextrin derivatives and pharmacologically acceptable salts thereof, and is in the form of a fat emulsion. | 07-30-2009 |
20100041769 | STABLE AND READY-TO-USE OIL-IN-WATER PROPOFOL MICROEMULSION - The present invention describes a new propofol-containing anesthetic pharmaceutical composition for parenteral administration, in the form of an oil-in-water microemulsion in which the oily phase is constituted by propofol in the form of particles with size comprised between 1 and 100 nm using a single surfactant selected from the group consisting of polyethylene glycol stearates with general formula C | 02-18-2010 |
20100048732 | Method of mediating Airway Smooth Muscle Construction Due to Airway Irritation - Methods of minimizing bronchospasm and contraction of airway smooth muscle due to irritation of the airway are provided. More particularly, a method is provided of mitigating bronchospasm or airway smooth muscle constriction due to irritation. This method includes administering to a subject in need of such treatment an amount of propofol or a derivative thereof effective to decrease the severity and/or duration of bronchospasm or airway smooth muscle constriction. Also provided are methods of up-regulating GABA mediated relaxation of airway smooth muscle at GABA | 02-25-2010 |
20100113611 | NOVEL USE OF HYDROXYTYROSOL - The invention relates to the use of hydroxytyrosol for inducing or enhancing cartilage repair or cartilage regeneration. Furthermore, the invention relates to nutraceutical and pharmaceutical compositions comprising hydroxytyrosol for regeneration and repair of cartilage injuries in joints, in particular of traumatic cartilage injuries. | 05-06-2010 |
20100130621 | USE OF HYDROXYTYROSOL AS ANTI-AGING AGENT - The present invention is directed to the use of (a composition comprising) hydroxytyrosol as anti-aging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is administered orally to animals. The present invention is further directed to anti-aging methods. “Anti-aging” meaning in the context of the present invention: retarding the aging processes in said animals, improving age-related physiological deficits in said animals and/or promoting a healthy aging in said animals. | 05-27-2010 |
20100160456 | Propofol Solution for Anesthetic Use - A transparent anesthetic solution for intravenous injection comprising at least 55% to 90% propofol dissolved in 10% to 45% of Macrogol 15 Hydroxystearate (SOLUTOL® HS 15), preferably having 25% by weight of Macrogol 15 Hydroxystearate (SOLUTOL® HS 15) for each 10.815 mg/ml of propofol. The solution may also include 0.0515 mg/ml of EDTA for each 10.815 mg/ml of propofol. The compositions result in decreased venous irritation and extends the shelf-life. | 06-24-2010 |
20100184868 | FORTIFICATION OF NUTRITIONAL PRODUCTS WITH OLIVE EXTRACTS CONTAINING HYDROXYTYROSOL AND HYDROXYTYROSOL FORTIFIED NUTRITIONAL PRODUCTS. - The present invention relates to nutritional products containing hydroxytyrosol, particularly fond products (i.e: fortified edible oils and fortified edible oil-containing products) and dietary supplements (i.e.: soft gel capsules containing fortified edible oils) with increased antioxidant capacity to be used as a source of hydroxytyrosol for preventing or treating cardiovascular diseases, plaque build-up in the arteries, arterial hypertension, and metabolic syndrome, thanks to the nutritional supply of an hydroxytyrosol rich composition. | 07-22-2010 |
20100222439 | BEVERAGE CONTAINING A POLYMERIC POLYPHENOL - This invention relates to a polymeric polyphenol containing beverage, In particular it relates to a substantially clear ambient temperature beverage comprising tea solids derived from fermented tea. The invention also relates to a method for improving the clarity of a polymeric polyphenol containing liquid composition. | 09-02-2010 |
20100240768 | NOVEL NUTRACEUTICALCOMPOSITIONS CONTAINING THYMOL AND/OR P-CYMENE OR PLANT EXTRACTS FOR COGNITION - The invention relates to a novel nutraceutical composition containing thymol and/or p-cymene, or a plant extract containing thymol or p-cymene as active ingredient(s). The compositions are useful for improvement of cognitive functions and psycho-social status, such as learning, memory and alertness, psychotic stability and maintenance. | 09-23-2010 |
20100267841 | Composition for Topical Use Containing an Extract of Stryphnodendron; Its Preparation As Well As Its Application - The present invention relates to topical compositions containing extracts of the plant genus | 10-21-2010 |
20100280132 | METHOD FOR MODIFYING POLYPHENOL CONTAINING PLANT MATERIALS AND MEDICAL USES OF MODIFIED POLYPHENOL PLANT CONTAINING MATERIALS - The present invention relates to a method for modifying polyphenol containing plant material(s), wherein said method comprises: mixing at least one polyphenol containing material and at least one solvent to provide a mixture; heating the mixture to eliminate bacterial species present to provide a heated mixture; adding at least one polyphenol modifying strain of lactic acid bacteria and optionally at least one protein source, in optional order or simultaneously, to the heated mixture to provide a fermentation mixture; and subjecting the fermentation mixture to conditions suitable for fermentation of the fermentation mixture to provide a mixture of modified polyphenol containing plant material(s); and optionally eliminating the polyphenol modifying strain of lactic acid bacteria to provide a mixture of modified polyphenol containing plant material(s) free from living lactic acid bacteria. | 11-04-2010 |
20110082217 | HIGH-CLARITY AQUEOUS CONCENTRATES OF 4-HEXYLRESORCINOL - The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions. | 04-07-2011 |
20110112201 | HYDROXYTYROSOL BENEFITS MITOCHONDRIA - Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue. | 05-12-2011 |
20110152383 | COMPOSITIONS COMPRISING BENZYL ALCOHOL DERIVATIVES AND FURTHER ANTIMICROBIAL ACTIVE COMPOUNDS - The present invention relates to a composition comprising or consisting of:
| 06-23-2011 |
20110269844 | THIN FILM WITH PROPOFOL ACTIVE INGREDIENT - An orally dissolvable thin film strip for the administration of the pharmaceutical active Propofol is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, the active Propofol, and optional additives. The slurry is then cast onto a substrate by slot die or knife-over-roll and is dried in an oven at a temperature that exceeds the boiling point of the solvent. The resulting dried thin film is cut into individual doses designed to administer 5 mg, 10 mg, or 20 mg of Propofol. | 11-03-2011 |
20110275722 | PROPOFOL BASED ANESTHETIC WITH PRESERVATIVE - The invention is a sterile pharmaceutical composition for parenteral administration comprised of an oil-in-water emulsion, in which Propofol is dissolved in a water-immiscible lipophilic agents, and surface stabilizing amphiphilic agent, and tonicity modifying water-soluble hydroxy group and preservative preferably, lipophilic organic compound (butylated hydroxytoluene, butylated hydroxyanisole) or its pharmaceutically acceptable salts thereof | 11-10-2011 |
20110281956 | USE OF THYMUS CAPITATUS EXTRACT, SATUREJA HORTENSIS EXTRACT, OR CARVACROL FOR TREATING METABOLIC DISEASES - Disclosed is an use of Spanish oregano ( | 11-17-2011 |
20120035271 | Stereoisomers Propofol Therapeutic Compounds - A (−)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic. | 02-09-2012 |
20120046368 | METHOD FOR PURIFYING 3,4-DIHYDROXYPHENYLGLYCOL (DHPG) FROM PLANT PRODUCTS - Process for purifying 3,4-dihydroxyphenylglycol (DHPG) from any part of the plant, from the products or by-products derived from olive trees or any other vegetable product of the families Oleaceae, Orobanchaceae, Plantaginaceae, Compositae, Lamiaceae, Acanthaceae and/or Scrophulariaceae, and which comprises 1 or more steps wherein the initial product is introduced into at least one ion-exchange resin column, and in potentially subsequent steps the product eluted in the preceding column is introduced into an ion-exchange resin and/or a non-ionic adsorption resin column. Moreover, it relates to the DHPG extract obtainable by means of the process disclosed and to the applications thereof. | 02-23-2012 |
20120196939 | Therapeutic Compounds - A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or pro drug thereof, is useful as an anesthetic. | 08-02-2012 |
20120202890 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES - The invention comprises compounds, methods of making, and methods of using. The compounds may have a backbone and three appended functional groups: one lipid, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. A variety of linkers between the backbone and functional groups may also be selected to optimize performance. | 08-09-2012 |
20120232163 | METHODS OF MAKING OLIVE JUICE EXTRACTS CONTAINING REDUCED SOLIDS - Solids, including fibers can be easily removed from olive juice by mixing the olive juice with a water-miscible solvent to form two phases and separating the phases. Preferably the solvent is ethanol. | 09-13-2012 |
20120238638 | BIOLOGICAL BIOCIDE ADDITIVES FOR POLYMERS - This invention pertains to a method of modifying biocides obtained from biological sources, namely polyphenols. The modified biocide may have protective groups to reduce or prevent the oxidation of these phenols. The protective groups may also control the rate of hydrolyzation with regards to biocide efficacy. This invention also includes a method wherein the modified biocide may be incorporated and stabilized into a substrate like plastic. | 09-20-2012 |
20120238639 | PHARMACEUTICAL COMPOSITION COMPRISING PROPOFOL - The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol. | 09-20-2012 |
20120259020 | TRANSDERMAL THERAPEUTIC SYSTEMS CONTAINING 4-N-BUTYLRESORCINOL - Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient. | 10-11-2012 |
20120283335 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics - Compounds of formula (I) wherein X is H or F and pharmaceutically acceptable salts thereof are useful as anesthetics. | 11-08-2012 |
20120289606 | Solid Formulations of Liquid Biologically Active Agents - The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent. | 11-15-2012 |
20120302645 | USE OF HYDROXYTYROSOL FOR IMPROVING MUSCLE DIFFERENTIATION - The use of hydroxytyrosol or an olive juice extract containing hydroxytyrosol for improving muscle differentiation and thus improving or maintaining the body's adaptation to exercise is disclosed. The pharmaceutical and nutraceutical compositions comprising hydroxytyrosol useful for conditions characterized by altered muscle differentiation especially under inflammatory conditions, such as delayed onset muscle soreness subsequent to strenuous exercise or sarcopenia are provided. | 11-29-2012 |
20120316248 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC INFECTIONS - Compositions for treating parasitic infections and methods of using the compositions to treat subjects with parasitic infections are provided. Methods of selecting compositions for use in treating parasitic infections are further provided. | 12-13-2012 |
20130059919 | Therapeutic Compounds - A (−)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic. | 03-07-2013 |
20130059920 | HYDROXYTYROSOL BENEFITS MUSCLE DIFFERENTIATION AND MUSCLE CONTRACTION AND RELAXATION - This invention is related to the use of hydroxytyrosol (“HT”), or an olive juice extract containing hydroxytyrosol as an agent to improve muscle differentiation and thus improve or maintain the body's adaptation to exercise. It is also related to the use of hydroxytyrosol (“HT”), or an olive juice extract containing hydroxytyrosol as an agent to improve calcium signaling and to improve skeletal muscle contraction and relaxation. It also relates to pharmaceutical and nutraceutical compositions useful for conditions characterized by altered muscle differentiation especially under inflammatory conditions, such as delayed onset muscle soreness subsequent to strenuous exercise or sarcopenia. | 03-07-2013 |
20130059921 | USE OF ESSENTIAL OIL OF OREGANO AND OF ROSEWOOD, OR CONSTITUENTS THEREOF, IN THE THERAPEUTIC TREATMENT OF KERATOSES - The present invention concerns various compositions comprising the essential oil of | 03-07-2013 |
20130072572 | New Signaling Molecule Involved in Ultraviolet Damage to Skin - The present invention includes a method of detecting ultraviolet radiation (UVR)-induced skin damage in a mammal. The present invention also includes a method of identifying a mammal at risk of developing U VR-induced skin damage, photoaging, or photocarcinogenesis. The present invention further includes a method of inhibiting UVR-induced skin damage in a mammal at risk of developing U VR-induced skin damage. The present invention also includes a method of reducing the level of Syk kinase in the skin of a mammal. The present invention further includes methods of treating or diagnosing a disease associated with a change of Syk kinase expression in the skin in a mammal. | 03-21-2013 |
20130072573 | PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL - Disclosed herein is a process for the preparation of highly pure 2,6-diisopropyl phenol (Formula I), which comprises reacting p-hydroxy benzoic acid (Formula II) with an alkylating agent in presence of aq. mineral acid followed by basilication and subsequent washings to yield 4-hydroxy-3,5-diisopropylbenzoic acid (Formula III) free of dimer impurity, 4, 4′-oxy-dibenzoic acid of Formula IV, ether impurity 3,5-di(propan-2-yl)-4-(propan-2-yloxy)benzoic acid of Formula V and the monoalkylated impurity 4-hydroxy-3-(propan-2-yl) benzoic acid of Formula VI; and decarboxylating 4-hydroxy-3,5-diisopropylbenzoic acid (Formula III) in presence of high boiling solvent and sodium hydroxide as a catalyst at high temperature to yield 2,6-diisopropyl phenol substantially free of ether impurity 1,3-di(propan-2-yl)-2-(propan-2-yloxy)benzene of Formula VII and monoalkylated phenol impurity 2-(propan-2-yl) phenol of Formula VIII. Propofol prepared by the process of the present invention is suitable for pharmaceutical use. | 03-21-2013 |
20130131186 | Microemulsion Preparation of High Concentration Propofol for Anesthetic Uses - The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2, 6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsion preparation. In a preferred two (2) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; and liquid propofol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 4% by weight of propofol to the volume of the microemulsion. In a four (4) component base composition, the base composition consists of: a surfactant, containing polyethylene glycol; liquid propofol; a water-immiscible solvent; and ethanol. The microemulsion is prepared by mixing the base composition with a carrier liquid, which results in the formation of a microemulsion containing concentrations of propofol of up to about 10% by weight of propofol to the volume of the microemulsion. | 05-23-2013 |
20130158128 | NATURAL, MULTIPLE USE AND RE-USE, USER SATURATED WIPES - The present invention relates to a wipe suitable for multiple re-use comprising a biopolymer matrix composition, said biopolymer matrix comprising from about 0.1% to about 40% of an essential oil, about 30% to about 95% of a biopolymer, and about 1% to about 50% of a carrier fluid wherein a limited amount of said essential oil can be released from said matrix composition when exposed to a liquid solution; and wherein an additional limited amount of said essential oil can be re-released repetitiously thereafter upon re-use with an additional exposure of a liquid solution to said wipe. | 06-20-2013 |
20130158129 | NATURAL, MULTIPLE RELEASE AND RE-USE COMPOSITIONS - A composition comprising a biopolymer matrix, said biopolymer matrix comprising from about 0.1% to about 40% of an essential oil, about 30% to about 95% of a biopolymer, and about 0% to about 50% of a carrier fluid wherein a limited amount of said essential oil can be released from said matrix composition when exposed to a liquid solution; and wherein an additional limited amount of said essential oil can be re-released repetitiously thereafter upon re-use with an additional exposure of a liquid solution. | 06-20-2013 |
20130184355 | Anti-Obesity and Anti-Dyslipidemic Effects of Oil Palm Phenolics in Preventing Atherosclerosis and Cardiovascular Disease - A composition comprising extracts containing oil palm phenolics in an amount effective for use in a method of reducing cholesterol biosynthesis and thus preventing obesity. The composition up regulates fatty acid beta oxidation and down regulates cholesterol biosynthesis in livers. The composition is useful for prevention of obesity associated diseases. The composition delays the onset of obesity and attenuates the inflammatory response of atherogenic diet, whereby the composition aids to suppress the inflammatory response thereby ameliorating artherosclerosis. The composition delays weight gain or obesity thereby preventing the effects of dyslipidemia. | 07-18-2013 |
20130217783 | Therapeutic Compounds - A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic. | 08-22-2013 |
20130245130 | NATURAL PRODUCT ANTIBIOTICS AND ANALOGS THEREOF - Provided herein are pure and isolated natural products and analogs thereof of Formula (I), (II), (III), and (IV), pharmaceutical compositions thereof, and methods of use, for example, for treating a bacterial infection. Further provided are methods useful in identifying an inhibitor of bacterial sugar fermentation in a bacterial strain, such as a compound (inhibitor) of Formula (I), (II), (III), or (IV): | 09-19-2013 |
20130296443 | SYSTEM AND METHOD OF TRANS-VENOUS PRE-AORTIC GANGLION ABLATION - A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion trans-venously and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell trans-venously to prevent regeneration. | 11-07-2013 |
20140031435 | PROPOFOL COMPOSITIONS AND METHODS FOR REDUCING PAIN ASSOCIATED WITH PROPOFOL INJECTION - The present invention pertains to pharmaceutical formulations containing propofol, methods for making such formulations, and methods for administering propofol at a pH above about 6.5, wherein the pain normally associated with propofol administration is reduced. | 01-30-2014 |
20140100290 | Method of treating a prostate condition - A method of treating a prostate cancer condition in a mammal in need of such treatment is disclosed. The method comprises administrating to the mammal an anti-prostate cancer effective amount of a compound of a plant essential oil. | 04-10-2014 |
20140142197 | DISINFECTANT FORMULATION - An aqueous disinfectant formulation comprising at least one phenolic compound of natural origin; a surfactant sufficient to form a solution or dispersion of the essential oil in an aqueous carrier; a solvent, and sufficient water to make 100 weight percent is described herein. | 05-22-2014 |
20140194531 | HYDROXYTYROSOL BENEFITS MITOCHONDRIA - Hydroxytyrosol or olive juice containing hydroxytyrosol ca in can he used to maintain or increase mitochondria(biogenesis in cardiac muscle, skeletal muscles, and liver tissue. | 07-10-2014 |
20140206773 | Therapeutic Compounds - A (−)-stereoisomer of formula (I): | 07-24-2014 |
20140243423 | Stable, Non-Irritating Topical Formulations of Hydroquinone - Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone. | 08-28-2014 |
20140323587 | SOLID FORMULATIONS OF LIQUID BIOLOGICALLY ACTIVE AGENTS - The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent. | 10-30-2014 |
20140336271 | Antimicrobial Compositions Containing Carvacrol and Thymol - Compositions having a combination of carvacrol and thymol are found to have synergistic antimicrobial activity against feed pathogens. | 11-13-2014 |
20150051297 | METHOD FOR DISINFECTING A SURFACE - The present invention relates to a method for disinfection involving an antimicrobial composition. It particularly relates to an antimicrobial method for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, acyclic terpene alcohols and a carrier provide synergistic antimicrobial action in a method for disinfection. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants. | 02-19-2015 |
20150051298 | METHODS FOR PRODUCING OPTIMAL STABLE NANOEMULSIONS AND FORMULATIONS OBTAINED THEREFROM - A method for producing stable nanoemulsions having a desired droplet size and functional properties tailored for use in a specific application (which is referred to as substantially optimizing composition) that includes selecting an aqueous phase; the aqueous phase comprising at least one ingredient from water, surfactant, co-surfactant and co-solvent, the aqueous phase being selected such that a stable nanoemulsions having a desired droplet size and functional properties tailored for use in a specific application is obtained, and selecting an organic phase comprising at least two ingredients from lipophilic component, oil, surfactant, co-surfactant and cosolvent, the organic phase being selected such that a stable nanoemulsions having a desired droplet size and functional properties tailored for use in a specific application is obtained, a nanoemulsion being formed when the organic phase is mixed with the aqueous phase. | 02-19-2015 |
20150087723 | MICROBIAL COMPOSITION - A synergistic microbicidal composition containing: (a) at least one microbicide selected from the group consisting of isopropyl methyl phenols and monosubstituted phenols and (b) at least antimicrobial alcohol is selected from the class consisting of acyclic terpene alcohols. | 03-26-2015 |
20150290121 | STABLE, NON-IRRITATING TOPICAL FORMULATIONS OF HYDROQUINONE - Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone. | 10-15-2015 |
20150306045 | METHOD OF REGULATING CIRCADIAN RHYTHM, AND METHOD OF PREPARING CIRCADIAN RHYTHM REGULATORY AGENT - Disclosed are a method of preparation and method of application of a circadian rhythm regulatory agent having as an active ingredient an alkylresorcinol represented by general formula (I) below and a circadian rhythm regulatory agent containing as an active ingredient an alkylresorcinol-containing extract from a cereal or a nut containing an alkylresorcinol of the following general formula (I). In the following general formula (I), R | 10-29-2015 |
20150335591 | DETOXIFYING ANTIMICROBIAL MOLECULAR COMPLEX - The invention relates to a food additive which includes at least one clay interspersed with volatile antimicrobial agents. Such an additive can be added to the feed of certain animals, in particular poultry and ruminants, in order to act as a growth promoter and to reduce the risks of infection, as well as the risks of intoxication by mycotoxins. | 11-26-2015 |
20160067159 | ANTIMICROBIAL SOAPS CONTAINING CARVACROL AND METHODS OF USING SAME - The present invention relates to antimicrobial formulations containing carvacrol and at least one of the following 2-phenoxyethanol, caprylyl glycol and hexylene glycol. | 03-10-2016 |
20160174550 | DISINFECTANT FORMULATION | 06-23-2016 |
20160184434 | AGENT FOR PROMOTING IN VIVO ABSORPTION OF HYDROXYTYROSOL AND DERIVATIVES THEREOF AND USE OF SAME - The purpose of the present invention is to provide a means for promoting the in vivo absorption of hydroxytyrosol or a derivative thereof, prolonging the in vivo residence time, and sustaining the effect. As a result of in-depth studies, the present inventors discovered that the in vivo absorption of hydroxytyrosol or a derivative thereof can be promoted and the in vivo residence time can be prolonged by using hydroxytyrosol or a derivative thereof in combination with a compound having a galloyl group. | 06-30-2016 |